GIM4 LEAD: Phase III Trial of Extended Adjuvant Therapy With Letrozole After Sequential Endocrine Therapy in Patients With HR+ Early Breast Cancer

May 31 - June 4, 2019; Chicago, Illinois
Extended adjuvant endocrine therapy with an additional 5 years of letrozole after tamoxifen prolonged DFS compared with standard-duration sequential endocrine therapy with letrozole in patients with HR-positive early breast cancer.
Format: Microsoft PowerPoint (.ppt)
File Size: 243 KB
Released: June 5, 2019

Acknowledgements

Provided by the USF Health

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Celgene Corporation
Novartis Pharmaceuticals Corporation
Puma Biotechnology

Related Content

On-demand webcast from a live Clinical Care Options (CCO) webinar with global expert perspectives on CDK4/6 inhibitors for early-stage HR+/HER2- breast cancer

Javier Cortes, MD, PhD Stephen R. D. Johnston, MA, FRCP, PhD Sara Tolaney, MD, MPH Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: July 21, 2021 Expired: July 20, 2022

From Clinical Care Options (CCO), video of pharmacist discussion of recently approved agents targeting HER2 and TROP2 for metastatic cancers

Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Program Director
Allison Butts, PharmD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) ABIM MOC: maximum of 0.25 Medical Knowledge MOC point(s) Released: July 20, 2021 Expired: July 19, 2022

Gain key clinical insights quickly with this short slideset from CCO on the latest data on treatment for patients with HR+/HER2- early breast cancer

Javier Cortes, MD, PhD Stephen R. D. Johnston, MA, FRCP, PhD Sara Tolaney, MD, MPH Released: July 9, 2021

Experts assess recurrence risk and use CDK4/6 inhibitors for HR+/HER2- early breast cancer in this on-demand webcast from a live Clinical Care Options (CCO) webinar

Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Sara Tolaney, MD, MPH Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: July 9, 2021 Expired: July 8, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue